Schenkein David P's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Feb 29, 2024
- Accession no.
- 0001439222-24-000042
- Filed
- Feb 29, 2024
- Trade date
- Feb 27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schenkein David PCIK 0001578200 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Common stock | MOption exerciseAcquired | +11,858 | $31.64 | +$375,187.12 | 134,712 | Direct | |
| Feb 27, 2024 | Common stock | SSaleDisposed | −11,858 | $33.60F1 | −$398,428.8 | 122,854 | Direct | |
| Feb 27, 2024 | Common stock | MOption exerciseAcquired | +57,471 | $31.64 | +$1,818,382.44 | 180,325 | Direct | |
| Feb 27, 2024 | Common stock | SSaleDisposed | −57,471 | $34.89F2 | −$2,005,163.19 | 122,854 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Common stock | MOption exerciseDisposed | −11,858 | $0.00 | $0 | 57,471 | Direct | |
| Feb 27, 2024 | Common stock | MOption exerciseDisposed | −57,471 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $33.02 to $34.41. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $34.64 to $35.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.